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The epidemiological, etiopathogenetic, laboratory and clinical features of serum lipid abnormalities
occuring in the course of HIVdisease are still poorly understood (especially when the supporting role of
single antiretroviral compounds is considered), while limited literature data are to date available regarding
themanagement of HIV-related dyslipidemia, as well as the e¤cacy and safety of dietary-exercise
programs, and that of selected hypolipidemic agents. At this time, a careful monitoring of serum lipid
pro¢le is needed during combination antiretroviral therapy including protease inhibitors, in order to
suggest a diet and hypolipidemic treatmentwhen applicable, and to prevent clinical sequelae related to
long-term dyslipidemia.The selection of an appropriate hypolipidemic agent is di¤cult, since no controlled
studies are available in this ¢eld, and possibly increased risks of pharmacologic interactions, toxicity and
impaired patient's adherence should be taken into consideration.Waiting for speci¢c guidelines for the
treatment of hypertriglyceridemia and hypercholesterolemia in the setting of HIVinfection, all available
literature reports dealing with themanagement of HIV-associated hyperlipidemia are brie£ydiscussed, on
the basis of personal clinical experience.
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D Y S L I P I D E M I A A N D H I V D I S E A S E : F RE Q U E N C Y ,
R I S K F A C T O R S , P A T H O G E N E S I S A N D C L I N I CA L
F E A T U R ES
A tendency towards the occurrence of dyslipidemia has been
reported in the course of HIV disease, even before the intro-
duction of highly active antiretroviral therapy (HAART):
according to Constans et al. [1], both frequency and severity of
hypertriglyceridemia and hypocholesterolemia appeared
related to the decrease of CD4 lymphocyte count, although
other authors pointed out frequent hypocholesterolemia dur-
ing advanced HIVdisease. However, since the introduction of
highly e¡ective combination antiretroviral regimens, multiple
metabolic abnormalities involving plasma lipids have been
increasingly recognized among HIV-infected patients under-
going prolonged HAART treatment (often carried out with
protease inhibitors, as the most potent anti-HIV drugs avail-
able since 1996) [2^25]. Hypertriglyceridemia, alone or com-
bined with hypercholesterolemia, represents the most
frequent laboratory ¢nding, and a picture similar to that of
mixed dyslipidemia is recognized in the large majority of
cases. Concurrent or related abnormalities frequently include
the association of hyperlipidemia, hyperinsulinemia and per-
ipheral insulin resistance [5,19,21^23,25^27], and that of
hyperlipidemia (mostly hypertriglyceridemia, followed by
hypercholesterolemia), with fat redistribution and the so-
called lipodystrophy syndrome, often involving protease-
inhibitor-treated patients, either adults [2^
5,16,19,21,22,28,29], or children [15,21]. In particular, abnorm-
alities of serum lipid pro¢le occuring during the ¢rst 3^12
months of HAART are usually characterized by a 50^300%
increase of triglyceride levels (compared with pretreatment
values), and a 20^50% rise in cholesterol levels (with asso-
ciated alterations of very lowdensity lipoproteins (VLDL) and
low density lipoproteins (LDL), and related apoproteins),
while plasma high density lipoprotein (HDL) cholesterol
levels usually show negligible changes. Serum lipid alterations
are expected to involve up to 50^70% of patients treated with
HAARTcontaining potent protease inhibitors (i.e. indinavir,
ritonavir, or nel¢navir), and include hypertriglyceridemia in
the majority (60^100%) of cases, followed by hypercholester-
olemia (10^70% of treated patients), while hyperglycemia
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may be associated in 5^30% of cases [2^5,7,12,13,15,18^
24,26,28^30]. On the other hand, low and comparable serum
lipid levels have been found in the majority of patients under-
going antiretroviral regimens excluding protease inhibitors, as
well as in untreated subjects [12 andR.Manfredi, unpublished
data].
When evaluating the relationship of dyslipidemia with the
use of single or combined protease inhibitors, hypertriglyceri-
demia proves signi¢cantly more frequent with ritonavir-
based regimens compared with indinavir- and nel¢navir-
based ones, and may reach very elevated values in patients
receiving ritonavir [6,8,12,13,21,23,29]. A mild to moderate
hypercholesterolemia seems more common among subjects
treated with ritonavir and probably nel¢navir, as opposed to
indinavir [21,31]. A recent study evaluating the compound-
speci¢c risk to develop hyperlipidemia in 93 patients treated
with protease inhibitors for at least 15months, a signi¢cant
relationship between hypercholesterolemia (but not elevated
HDL-cholesterol) and treatment with ritonavir (as opposed to
indinavir or nel¢navir) was demonstrated, while hypertrigly-
ceridemia was related to ritonavir use only; the combination
of ritonavir or nel¢navir with saquinavir did not induce
further alterations of plasma lipid levels [21]. In a very recent
cohort study carried out on 221patients observed over 5 years,
an independent associationwas found between use of protease
inhibitors and onset of hyperglycemia, hypercholesterolemia,
hypertriglyceridemia and lipodystrophy (cumulative fre-
quency: 5%, 24%, 19% and 13%, respectively); these altera-
tions proved independent from the immunological and
virologic outcome of HIV disease, and no signi¢cant di¡er-
ence was recognized among patients treated with di¡erent
protease inhibitors, when excluding a preferential link
between hypertriglyceridemia and ritonavir use [29]. Slight
or negligible alterations of serum lipids are usually observed
during treatment with saquinavir hard gel compared with
indinavir, ritonavir and nel¢navir [21,26], while the incidence,
features and severity of dyslipidemia with the soft gel formu-
lation of saquinavir, as well as for other recently introduced
protease inhibitors (such as amprenavir and ABT-078), is still
being investigated. The development of hyperlipidemia dur-
ing protease inhibitor administration appears to be both dose-
and time-related, with the greatest levels usually related to
regimens containing one full-dose drug administered for at
least 6months [6,8,12,13,21,23,29]. Baseline and subsequent
CD4 lymphocyte count and plasmaviral load do not show a
signi¢cant relationship with the development of hyperlipide-
mia during HAART, while the role of age, gender, body mass
index and prior serum triglyceride and cholesterol levels is still
discussed [23,29]. Two challenging problems in the manage-
ment of HIVdisease in the future, such as lipodystrophy and
the fat redistribution syndrome, are frequently (but not
always) associated with dyslipidemia; in a recent study [22],
lipodystrophy was signi¢cantly related to a rise in serum cho-
lesterol, LDL cholesterol, triglycerides and apolipoprotein-B,
but a concurrent experience failed to recognize a relationship
between protease inhibitor-related hyperlipidemia and lipo-
dystrophy in a series of HIV-infectedwomen [16]. In our series
of 200 patients randomly selected from approximately 1000
subjects followed at our reference outpatient center, a crude
37.5% rate of hyperlipidemia was found, with both frequency
and severity of hypertriglyceridemia and hypercholesterole-
mia clearly related to the administered antiviral drugs: as pre-
viously recorded [6,13,21], both the occurrence and severity of
hypertriglyceridemiawere associatedwith ritonavir use, while
hypercholesterolemia was signi¢cantly less frequent, but a
relationship with indinavir or ritonavir administration was
demonstrated, di¡erently from prior reports [21,31]. On the
other hand, patients given nucleoside analogs with or without
non-nucleoside reverse transcriptase inhibitors had neither a
di¡erent frequency nor di¡erent mean plasma triglyceride and
cholesterol levels, compared with untreated subjects, so that
our data seemed to exclude a relevant role of these two last
drug groups in prompting hyperlipidemia. Similarly to data
reported by Christe¡ et al. [22], lipodystrophy occurred only
in indinavir- and ritonavir-treated individuals (nel¢navir
recipients were not evaluated in detail), and was related to
hypertriglyceridemia and hypercholesterolemia in 87.5% and
21.9% of cases, respectively. Finally, severe clinical conse-
quences of hyperlipidemia did not appear during the 12-
month observation period, but an asymptomatic rise of amy-
lase and/or lipase levels occured almost exclusively when
hypertriglyceridemia was present, while hyperglycemia was
found mostly in patients with indinavir- or ritonavir-asso-
ciated hyperlipidemia (R.Manfredi et al., unpublished data).
From a pathogenic point of view, multiple metabolic path-
ways have been postulated to explain the spectrum of serum
lipid abnormalities and related conditions, which occur with
increasing frequency in HIV-infected patients receiving
HAART. Although the large majority of studies recognized
the use of potent protease inhibitors as the most probable risk
factor for dyslipidemia, through either the induction of per-
ipheral resistance to insulin, or the possible homology of the
catalytic region of HIV protease to a couple of proteins con-
trolling lipid metabolism, however, HIV infection itself, the
suppression of HIV replication related to HAART, inhibition
of lipoprotein-lipase possibly induced by tumor necrosis fac-
tor-a, or multiple subtle changes in endocrine and metabolic
homeostasis (including a persistent imbalance between per-
ipheral lipolysis and lipogenesis), have been suggested by dif-
ferent authors as contributing causes of these metabolic
disorders [3,4,16,19,20,22,23,25,28,34^37]. On the other hand,
the pathogenesis of the lipodystrophy (fat redistribution) syn-
drome appears to be multifactorial in origin, and only par-
tially related to that of dyslipidemia. Accelerated apoptosis of
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peripheral adipocytes (possibly supported by antiretroviral
agents other than protease inhibitors), is increasingly pointed
out by recent literature studies [3^
5,12,16,19,22,24,28,32,34,36]. Nucleoside analogs may act
through mitochondrial toxicity [4,16,22,32,35,36,38,39]: in
particular, prolonged stavudine or lamivudine administration
could be responsible for an increased risk of peripheral lipoa-
trophy and fat redistribution, often related to increased plasma
triglyceride levels [16,32]. Finally, even regimens containing
non-nucleoside reverse transcriptase inhibitors such as nevira-
pine, have been related to lipodystrophy (but not to dyslipide-
mia), in patients naive to protease inhibitors [33,34].
Since the availability of HAART led to an extraordinary
reversal of the natural history of HIVdisease [40], prolonged
metabolic disturbances become of relevant concern, since they
could signi¢cantly act on the long-term prognosis of people
with HIV infection, and alter their life expectancy. Patients
have bene¢ted by the introduction of e¡ective therapeutic
strategies; moreover, serious psychological consequences due
to esthetic alterations are expected from both lipodystrophy
and the fat redistribution syndrome.The possible pathological
and clinical consequences of HIV-associated dyslipidemia are
not completely known, but several observations recorded an
increased risk of premature coronary heart disease [9^
11,21,41^43], as well as peripheral atherosclerosis [10], acute
pancreatitis [6,8,14,44], cutaneous xanthomas [13] and avascu-
lar bone necrosis [23]. Since the long-term risk of untreated
hyperlipidemia is still unknown, as is the relationship between
the temporal trend of dyslipidemia and continued, inter-
rupted, or modi¢ed HAART, therefore lipid-lowering strate-
gies should be applied as soon as possible, although they
would be required for an extended period of time, and add to a
complex pharmacologic regimen (such as the antiretroviral
one).
P E R S P EC T IV E S O F M A N A G E M EN T
Aggressive strategies aimed at preventing and controlling
HIV-related metabolic abnormalities are strongly needed,
since accelerated atherosclerosis, cardio- and cerebrovascular
disease, and pancreatitis are increasingly reported [6,8^
11,14,21,41^44], even in the absence of lipodystrophy [10].
From a diagnostic point of view, frequent and careful moni-
toring of plasma lipid levels becomes mandatory in all patients
given potent antiretroviral combinations, especially those
containing ritonavir, indinavir and nel¢navir (alsowhen asso-
ciatedwith saquinavir hard gel).Moreover, secondary hyperli-
pidemia due to diabetes mellitus, abnormal thyroid or kidney
function, or concurrent drug treatments, must be carefully
ruled out [23,31].
Unfortunately, no speci¢c guidelines exist for the manage-
ment of HIV-related dyslipidemia, so that international
recommendations for both dietary and drug treatment of
hypertriglyceridemia and hypercholesterolemia should be fol-
lowed to lower the risk of atherogenic complications
[23,31,45^47], until therapeutic measures speci¢cally tailored
to patients with HIVdisease will become available, following
the completion of controlled studies.
A limited-to-signi¢cant reversion of metabolic abnormal-
ities related to protease inhibitor administration was demon-
strated in patients who replaced these drugs with other
compounds belonging to this class (especially when ritonavir
or indinavir were changed to nel¢navir) [5,7,8,13,14,21,23,30].
A more clear bene¢cial e¡ect on both hyperlipidemia and
lipodystrophy was also observed after switch from a protease
inhibitor-containing regimen to a HAART including nevira-
pine [20]. On the other hand, substitution of a single drug due
to tolerability issues is acceptable only when antiretroviral
therapy is e¡ective, while in patients with failing HAART
multiple concurrent changes of anti-HIV compounds should
be considered [23,40].
A hypolipidemic diet and increased physical exercise may
act favorably on serum lipid levels [12], but pharmacological
treatment becomes mandatory when elevated lipidemia per-
sist, since suspension or withdrawl of e¡ective antiretroviral
therapy is not recommended [40]. No controlled data are
available at present regarding the e¤cacy of lipid-lowering
drugs in the management of HIV-related dyslipidemia
[8,12,13,17,23,31,41,48], so that no speci¢c treatment guidelines
are available for HIV-infected patients. As a result, drug selec-
tion should be based on current recommendations for the gen-
eral population [23,31,45^47,49], even though multiple special
issues regarding HIVdisease and its treatment should be care-
fully considered. In fact, potential advantages of reducing the
frequency and severity of hypertriglyceridemia and hypercho-
lesterolemia (and indirectly related consequences), should be
balanced with risks of drug^drug interactions with antiretro-
viral compounds and other drugs of common use in HIV-
infected patients (i.e. antimicrobial agents), an increased risk of
toxicity or intolerance (conditioned by concurrent drugs and
illnesses), e¡ects on concurrent HIV-related diseases, and
impaired patient's adherence to multiple, long-term pharma-
cological regimens. In particular, a possible increased intoler-
ance to ¢brates and especially statins when combined with
hepatic cytochrome P450 inhibitors (such as HIV protease
inhibitors and delavirdine) has been claimed. Associations
with oral hypoglycemic agents, imidazoles and a number of
antimicrobial compounds are questionable [7,12,21,
23,31,45,50].When considering the pharmacological features
of the available hypolipidemic agents, and common problems
related to HIVdisease treatment (mainly the possible interac-
tions with hepatic detoxi¢cation pathways), all ¢brates, £uvas-
tatin, atorvastatin and possibly rapid-release niacin,
pravastatin and cerivastatin, may be reasonable ¢rst choices,
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while lovastatin, simvastatin and bile acid sequestrants should
not be selected because of their potentially added toxicity,
expected drug interactions (especially with protease inhibitors
and delavirdine), or poor activity against hypertriglyceridemia
[13,23,31,51], while a combination of ¢brates and statins is not
recommended, due to increased skeletal muscle toxicity.
Pending a better knowledge of the pathogenesis of HIV-
related dyslipidemia and lipodystrophy, possibly suggesting
an etiological treatment of these conditions [21,22,25,31,37],
the administration of hypolipidemic agents has been recently
attempted in some anecdotal case reports [8,13,41,48,51], and in
small uncontrolled studies [12,17], though with alternate suc-
cess. In a patient with elevated serum triglyceride and choles-
terol levels while on indinavir, treatment with gem¢brozil
(600mg twice daily) did not avoid coronary heart disease [41].
In another subject su¡ering from a remarkable ritonavir-
related hypertriglyceridemia, either feno¢brate (300mg/day)
plus a lipid-lowering diet, or omega-3 marine triglyceride
capsules (10 g/day), had no relevant e¡ect [8]. One more
patient with a severe mixed hyperlipidemia failed gem¢brozil
(600mg/day) treatment while on a ritonavir^saquinavir
combination, while withdraval of all antiretroviral drugs and
associated lovastatin (20mg/day) and subsequently niacin
allowed re-introduction of a nel¢navir^saquinavir associa-
tion, after that a signi¢cant decrease of lipemia was reached
[13]. Atorvastatinwas used successfully in 15 patients with ele-
vated cholesterol and triglyceride levels after a mean period of
7months of ritonavir-including HAART; a signi¢cant
decrease (at least 25%) in serum levels was obtained after 3
months and maintained up to 15 months, in the absence of
toxicity [51]. More recently, feno¢brate proved e¡ective in
two patients who developed elevated triglyceridemia during
treatment with protease inhibitors, and led to a> 75% drop
of plasma triglyceride levels after 10months of administration
[48]. Finally, Henry et al. [12] managed patients with a moder-
ate increase of serum lipid levels with a diet-exercise pro-
gramme, while 24 subjects with a more pronounced
hyperlipidemia (or failing the ¢rst step of management)
received gem¢brozil (600mg twice daily), or atorvastatin
(initial dose, 10mg/day). A high failure rate was recognized in
both the diet-exercise group (12 patients of 20), and in the
gem¢brozil group (19 cases of 25), but the association of gem-
¢brozil plus atorvastatin obtained a 30% and 60% drop of
cholesterol and triglyceride levels, respectively, obtained in 19
patients within 6.5months of treatment, in the absence of rele-
vant toxicity [12]. A retrospective survey of eight patients (¢ve
with hypertriglyceridemia observed while on ritonavir), was
reported by Hewitt et al. [17]: gem¢brozil administration
(600mg twice daily) attained a 83% reduction of peak serum
triglyceride levels, after a mean period of 89 (range 37^255)
days, in the absence of untoward events, while serum choles-
terol levels remained slightly elevated and unchanged by gem-
¢brozil administration.
In our series, 49 patients with elevated triglyceridemia and
cholesterolemia persisting for> 6months while on ritonavir-
or indinavir-containing HAART, and unresponsive to a> 3-
month diet, started a treatment with a single daily dose of
beza¢brate (400mg). A reduction of triglyceride and choles-
terol levels >35% and >25% vs. respective baseline values
was obtained within 6months, with over two-thirds of sub-
jects reaching a normal triglyceridemia after 6^9months, and
all those with hypercholesterolemia attaining normal plasma
levels within 9months in the absence of adverse events, and
without di¡erence of therapeutic response according to the
underlying protease inhibitor regimen, although no signi¢-
cant modi¢cation of the eventually concurrent lipodystrophy
syndrome was noticed (R. Manfredi et al., unpublished data).
Beza¢brate is a ¢brate hypolipidemic agent, e¡ective in the
treatment of hypertriglyceridemia and mixed hyperlipidemia
[45,50], because of its extended activity on the hepatic synth-
esis of both triglycerides and cholesterol, lipoprotein lipase,
acetyl-CoA carboxylase, and the concomitant inhibition of
peripheral lipolysis and improved glycemic control. Due to
these features, beza¢brate is expected to act favorably against
the dyslipidemic syndrome commonly a¡ecting HIV-infected
patients treated with protease inhibitor-containing HAART,
and characterized by elevated serum triglyceride levels, fre-
quently accompanied by high total cholesterol levels [45,50].
As demonstrated by our experience, one single drug adminis-
tered once daily, may signi¢cantly control diet-resistant
mixed hyperlipidemia, avoiding the administration of asso-
ciated compounds (above all the combination of ¢brate and
statins, which is usually discouraged) [45,50].
C O N C L U S IO N
In conclusion, clinicians caring for patients with HIV disease
treated with a protease inhibitor-containing HAART should
ensure periodic monitoring of serum lipid levels, in order to
plan dietary suggestions and eventually hypolipidemic treat-
ment.The e¡ective control of lipid abnormalities may prevent
the occurrence of severe and even life-threatening clinical
problems in patients who undergo long-term treatment with
protease inhibitors, as the most potent antiretroviral drugs
until now available. Controlled studies are warranted, in order
to establish speci¢c guidelines for the management of dyslipi-
demia and related conditions in the setting of HIVdisease.
R E F ER E N C ES
1. Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-
infected patients: a prospective study in 95 patients.EurJClin Invest
1994; 24: 416^20.
äðá Clinical Microbiology and Infection, Volume 6 Number 11, November 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 579±584
2. Viraben R, Aquilina C. Indinavir-associated lipodystrophy.
AIDS1998;12: F37^9.
3. Miller KD, Jones E,Yanovski JA, Shankar R, FeuersteinY, Fallon
J.Visceral-abdominal fat accumulation associatedwith use of indi-
navir. Lancet1998; 351: 871^5.
4. Lo JC, Mulligan K,Tai VW, Algren H, Schambelan M. `Bu¡alo
hump' in menwithHIV-1 infection. Lancet1998; 351: 867^70.
5. CarrA, Samaras K, Burton S et al.A syndrome of peripheral lipo-
dystrophy, hyperlipidaemia and insulin resistance in patients
receivingHIVprotease inhibitors.AIDS1998;12: F51^8.
6. Di Perri G, Del Bravo P, Concia E. HIV-protease inhibitors. N
EnglJMed1998; 339: 773^4.
7. Stocker DN, Meier PJ, Stoller R, Fattinger KE.`Bu¡alo hump' in
HIV-1 infection. Lancet1998; 352: 320^1.
8. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked
hypertriglyceridemia associated with ritonavir therapy. AIDS
1998;12: 1393^4.
9. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M.Vascular com-
plications associated with use of HIV protease inhibitors. Lancet
1998; 351: 1958^9.
10. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE.Vascular
complications associatedwith use of HIVprotease inhibitors. Lan-
cet1998; 351: 1958.
11. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications asso-
ciatedwith use of HIVprotease inhibitors. Lancet1998; 351: 1959.
12. Henry K,Melroe H, Huebesch J, Hermundson J, Simpson J. Ator-
vastatin and gem¢brozil for protease inhibitor-related lipid
abnormalities. Lancet1998; 352: 1031^2.
13. Echevarria KL, HardinTC, Smith JA. Hyperlipidemia associated
with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859^
63.
14. Clark Perry R, Cushing HE, Deeg MA, Prince MJ. Ritonavir,
triglycerides, and pancreatitis.Clin InfectDis1999; 28: 161^2.
15. Arpadi SM, Cu¡ PA, Horlick M, Kotler DP. Visceral obesity,
hypertriglyceridemia and hypercortisolism in a boy with perina-
tally acquired HIV infection receiving protease inhibitor-contain-
ing antiviral treatment.AIDS1999;13: 2312^3.
16. Gervasoni C, Ridolfo AL,Tri¢ro© G et al. Redistribution of body
fat in HIV-infected women undergoing combined antiretroviral
therapy.AIDS1999;13: 453^71.
17. Hewitt RG, Shelton MJ, Esch LD. Gem¢brozil e¡ectively lowers
protease inhibitor-associated hypertriglyceridemia in HIV-1 posi-
tive patients.AIDS1999;13: 868^9.
18. Berthold HK, Parhofer KG, Ritter MM et al. In£uence of protease
inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;
246: 567^75.
19. Marti¨nez E, Gatell JM. Metabolic abnormalities and body fat
redistribution in HIV-1 infected patients: the lipodystrophy syn-
drome.CurrOpin InfectDis1999;12: 13^9.
20. Marti¨nez E, Conget I, Lozano L, Casamitjana R, Gatell JM.
Reversion of metabolic abnormalities after switching from HIV-
1protease inhibitors to nevirapine.AIDS1999;13: 805^10.
21. Pe¨riard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in
HIV-infected individuals treated with protease inhibitors. The
SwissHIVCohort StudyCirculation1999;100: 700^5.
22. Christe¡ N, Melchior JC, de Truchis P, Perronne C, Nunez EA,
Gougeon ML. Lipodystrophy de¢ned by a clinical score in HIV-
infected men on highly active antiretroviral therapy: correlation
between dyslipidaemia and steroid hormone alterations. AIDS
1999;13: 2251^60.
23. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV pro-
tease inhibitor use: pathophysiology, prevalence, risk factors and
treatment. ScandJ InfectDis 2000; 32: 111^23.
24. Pujol RM, Domingo P, Xavier-Matias G et al. HIV-1 protease
inhibitor-associated partial lipodystrophy: clinicopathologic re-
viewof14 cases. JAmAcadDermatol 2000; 42: 193^8.
25. CarrA. HIVprotease inhibitor^related lipodystrophy syndrome.
Clin InfectDis 2000; 30: S135^42.
26. Walli R, Herfort O,Michl GM et al.Treatment with protease inhi-
bitors associated with peripheral insulin resistance and impaired
oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:
F167^73.
27. Marti¨nez E, Casamitjana R, Conget I, Gatell JM. Protease inhibi-
tor-associated hyperinsulinaemia.AIDS1998;12: 2077^9.
28. Yanovski JA, Miller KD, Kino T et al. Endocrine and metabolic
evaluation of human immunode¢ciency virus-infected patients
with evidence of protease inhibitor-associated lipodystrophy. J
ClinEndocrinolMetab1999; 84: 1925^31.
29. Tsiodras S,MantzorosC,Hammer S, SamoreM.E¡ects of protease
inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy:
a 5-year cohort study.ArchInternMed2000;160: 2060^6.
30. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A.
`Bu¡alo hump' in HIV-1 infection. Lancet1998; 352: 320.
31. Currier JS. How tomanage metabolic complications of HIV ther-
apy: what to do while we wait for answers. AIDS Read 2000; 10:
162^9,171^4.
32. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of
peripheral fat wasting (lipodystrophy) in patients receiving long-
term nucleoside analogue therapy.AIDS1999;13: 1659^67.
33. AldeenT,Wells C, Hay P,Davidson F, LauR. Lipodystrophy asso-
ciated with nevirapine-containing antiretroviral therapies. AIDS
1999;13: 865^7.
34. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of
HIV-1 protease inhibitor-associated peripheral lipodystrophy,
hyperlipidaemia, and insulin resistance. Lancet1998; 351: 1881^3.
35. Saint-MarcT,Touraine JL.`Bu¡alo hump' in HIV-1 infection. Lan-
cet1998; 352: 319^20.
36. Kotler DP, Rosenbaum K,Wang J, Pierson RN. Studies of body
composition in HIV-infected and control subjects. JAcquir Immune
De¢cSyndrHumRetrovirol1999; 29: 228^37.
37. Purnell JQ, Zambon A, Knopp RH et al. E¡ect of ritonavir on
lipids and post-heparin lipase activities in normal subjects. AIDS
2000;14: 51^7.
38. KakudaTN, Brundage RC, Anderson PL, Fletchner CV. Nucleo-
side reverse transcriptase inhibitor-induced mitochondrial toxi-
city as an etiology for lipodystrophy.AIDS1999;13: 2311^2.
39. Madge S, Kinloch-de-Loes S, Mercey D, Johnson M,Weller I.
Lipodystrophy in patients naive to protease inhibitors. AIDS
1999;13: 735^7.
40. Carpenter CCJ, Cooper DA, Fischl MA et al. Antiretroviral ther-
apy in adults. Updated recommendations of the International
AIDSSociety-USA Panel. JAMA 2000; 283: 381^90.
41. Henry K, Melroe H, Huebesch J et al. Severe premature coronary
arterydiseasewith protease inhibitors. Lancet1998; 351: 1328.
42. Eriksson U, Opravil M, Amann FW, Scha¡ner A. Is treatment
with ritonavir a risk factor for myocardial infarction in HIV-
infected patients?AIDS1998;12: 2079^80.
43. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected
men receiving protease inhibitors.Ann InternMed1999;131: 548.
44. Mirete G, Masia M, Gutierrez F, Mora A, Escolano C, Maestre
A. Acute pancreatitis as a complication of ritonavir therapy in a
patient with AIDS. EurJClinMicrobiol InfectDis1998;17: 810^1.
äðâManfredi Dyslipidemia and HIV infection
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 579±584
45. Goa KL, Barradell LB, Plosker GL. Beza¢brate. An update of its
pharmacology and use in the management of dyslipidaemia.
Drugs1996; 52: 725^53.
46. Criqui MH. Triglycerides and cardiovascular disease. A focus on
clinical trials. EurHeartJ1998;19(Suppl. A): A36^9.
47. Mooney A. Treating patients with hypertriglyceridemia saves
lives: triglyceride revisited.CurrMedResOpin1999;15: 65^77.
48. Thomas JC, Lopez-Virella MF, Del Bene VE et al. Use of feno¢-
brate in the management of protease inhibitor-associated lipid
abnormalities. Pharmacotherapy 2000; 20: 727^34.
49. National Cholesterol Education Program. Second report of the
National Cholesterol Education Program (NCEP) Expert Panel
on detection, evaluation, and treatment of high blood cholesterol
in adults.Circulation1994; 89: 1329^44.
50. Miller DB, Spence JD. Clinical pharmacokinetics of ¢bric acid
derivatives (¢brates).ClinPharmacokinet1998; 34: 155^62.
51. Murillas J, MartinT, Ramos A, Portero JL. Atorvastatin for pro-
tease inhibitor-related hyperlipidaemia.AIDS1999;13: 1424^5.
äðã Clinical Microbiology and Infection, Volume 6 Number 11, November 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 579±584
